You are here

  • Home
  • Archive
  • Volume 94, Issue 2
  • Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?

Article Text

Article menu
Download PDFPDF
Editorial
Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?

https://doi.org/10.1136/bjo.2009.159863

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding The Cole Eye Institute, PKK's employer, receives research grant support on his behalf from Novartis, QLT and Genentech.

    • Competing interests PKK has received honoraria from Genentech, QLT and Novartis that have been disclosed and approved by the Cleveland Clinic Conflict of Interest Committee.

    • Ethics approval Ethics approval was provided by the sites in the SUMMIT programme.

    • Patient consent Obtained.

    • Provenance and peer review Commissioned; externally peer reviewed.

    Linked Articles